Tucidinostat（Cat No.:I009908）, also known as Chidamide, is a selective histone deacetylase (HDAC) inhibitor that targets HDAC subtypes 1, 2, 3, and 10. By inhibiting HDAC activity, Tucidinostat induces histone acetylation, leading to the reactivation of tumor suppressor genes and promoting cancer cell apoptosis and cell cycle arrest. It is primarily used in the treatment of hematological malignancies, such as peripheral T-cell lymphoma (PTCL) and other cancers. Tucidinostat’s selective inhibition of specific HDACs minimizes off-target effects, making it a valuable agent in targeted cancer therapies and epigenetic research.
| Catalog Number | I009908 |
| CAS Number | 1616493-44-7 |
| Synonyms | Tucidinostat; HBI-8000; HBI 8000; HBI8000 Chidamide; CS-055; CS 055; CS055;(E)-N-(2-amino-4-fluorophenyl)-4-((3-(pyridin-3-yl)acrylamido)methyl)benzamide |
| Molecular Formula | C22H19FN4O2 |
| Purity | ≥95% |
| Target | Histone Deacetylase Inhibitor |
| Solubility | Soluble in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | N-(2-amino-4-fluorophenyl)-4-[[[(E)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide |
| InChI | InChI=1S/C22H19FN4O2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+ |
| InChIKey | SZMJVTADHFNAIS-BJMVGYQFSA-N |
| SMILES | C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N |
| Reference | </br>1: Gao S, Li X, Zang J, Xu W, Zhang Y. Preclinical and clinical studies of chidamide (CS055/HBI-8000), an orally available subtype-selective HDAC inhibitor for cancer therapy. Anticancer Agents Med Chem. 2016 Sep 1. [Epub ahead of print] PubMed PMID: 27592546.</br>2:Hasegawa H, Bissonnette RP, Gillings M, Sasaki D, Taniguchi H, Kitanosono H, Tsuruda K, Kosai K, Uno N, Morinaga Y, Imaizumi Y, Miyazaki Y, Yanagihara K. Induction of apoptosis by HBI-8000 in adult T-cell leukemia/lymphoma is associated with activation of Bim and NLRP3. Cancer Sci. 2016 Aug;107(8):1124-33. doi: 10.1111/cas.12971. Epub 2016 Jun 22. PubMed PMID: 27193821; PubMed Central PMCID: PMC4982578.</br>3:Dong M, Ning ZQ, Xing PY, Xu JL, Cao HX, Dou GF, Meng ZY, Shi YK, Lu XP, Feng FY. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol. 2012 Jun;69(6):1413-22. doi: 10.1007/s00280-012-1847-5. Epub 2012 Feb 24. PubMed PMID: 22362161. |
